ID
42247
Descripción
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with ACS. https://clinicaltrials.gov/ct2/show/NCT00391872
Link
https://clinicaltrials.gov/ct2/show/NCT00391872
Palabras clave
Versiones (3)
- 28/11/15 28/11/15 -
- 14/4/21 14/4/21 - Ahmed Rafee, MD
- 15/4/21 15/4/21 - Ahmed Rafee, MD
Titular de derechos de autor
AstraZeneca
Subido en
15 de abril de 2021
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Excerpt PLATO Acute coronary Syndrome NCT00391872
Section Investigational Products
Similar models
Section Investigational Products
C1608718 (UMLS CUI [1,2])
C1608718 (UMLS CUI [1,2])
C0070166 (UMLS CUI [1,2])
C0070166 (UMLS CUI [1,2])
Sin comentarios